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antibiotic treatment (11/10 days; p = 0.75) or length of hospi-
tal stay (16.5/16 days; p = 0.27) between the groups. The use 
of pegfilgrastim resulted in 12% higher treatment-related 
costs when compared to filgrastim, without reaching statis-
tical significance (p = 0.38).  Conclusion: Pegfilgrastim ap-
pears to be equivalent to filgrastim after high-dose BEAM 
followed by APBSCT in the treatment of lymphoma patients. 
 Copyright © 2010 S. Karger AG, Basel 
 Introduction 
 Autologous peripheral blood stem cell transplantation 
(APBSCT) is a widely performed treatment modality for 
patients with multiple myeloma or relapsed/refractory 
Hodgkin’s lymphoma (HL) and aggressive non-Hodg-
kin’s lymphoma (NHL)  [1–4] . According to the European 
Group for Blood and Marrow Transplantation database, 
6,734 autologous stem cell transplantations were per-
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 Abstract 
 Objective: To evaluate the impact of pegfilgrastim on en-
graftment, hospital stay and resources in patients with 
Hodgkin’s and non-Hodgkin’s lymphoma after conditioning 
with high-dose BEAM followed by autologous peripheral 
blood stem cell transplantation (APBSCT) compared with fil-
grastim.  Methods: We reviewed patient charts and our pro-
spective transplantation database for clinical data from the 
post-transplant period. An integrated cost analysis, includ-
ing the use of blood products and length of hospital stay, 
was also performed.  Results: Fourteen (26%) patients with 
Hodgkin’s lymphoma and 40 (74%) patients with non-Hodg-
kin’s lymphoma were analyzed. Thirty-four (68%) patients 
received single-dose pegfilgrastim (6 mg), and 20 (32%) pa-
tients received daily filgrastim (5   g/kg) after APBSCT. No 
differences were observed regarding duration of neutrope-
nia grade 4 (pegfilgrastim median 7 days/filgrastim median 
8 days; p = 0.13), thrombocytopenia grade 4 (7/9.5 days, re-
spectively; p = 0.21), fever (4.5/2 days; p = 0.057), intravenous 
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formed in lymphoma patients in 2008 (1,919 for HL pa-
tients and 4,815 for NHL patients)  [5] . Treatment-related 
mortality is less than 5% and most often due to infectious 
complications during the post-transplant period  [6] . To 
reduce the time to engraftment and eventually the risk for 
infections, many transplantation centers have established 
the use of granulocyte-colony stimulating factors (G-
CSF) in the APBSCT routine, although data on their clin-
ical benefit and general recommendations are still am-
biguous  [7–8] . Due to their short half-life, daily injections 
are necessary until neutrophil recovery has been achieved.
 Pegfilgrastim (Neulasta © , Amgen) is the pegylated 
form of the G-CSF filgrastim (Neupogen © , Amgen). This 
long-term formulation has the advantage over filgrastim 
of a single application after the myeloablative chemother-
apy, thus improving patient comfort and administration 
safety.
 Here we report on the efficacy of pegfilgrastim in 
comparison to filgrastim in patients with NHL or HL re-
ceiving unmodified high-dose BEAM as conditioning 
regimen followed by APBSCT at our Stem Cell Trans-
plantation Center in Zürich during the last 4 years. We 
analyzed only lymphoma patients receiving unmodified 
high-dose BEAM, to avoid any possible bias based on the 
heterogeneity of the administered conditioning regimens 
 [9–11] . We also placed a special emphasis on possible dif-
ferences in treatment-related costs during the post-trans-
plant period.
 Patients and Methods 
 Patients with NHL or HL receiving high-dose BEAM as con-
ditioning regimen followed by APBSCT during the last 4 years 
(2006–2009) at our center were analyzed. The study was approved 
by our local ethic committee.
 Patients received either pegfilgrastim or daily filgrastim after 
APBSCT. Pegfilgrastim was administered as single fixed dose of 
6 mg subcutaneously at day +1 after stem cell retransfusion. Fil-
grastim was given at a dose of 5   g/kg body weight subcutane-
ously once daily, starting at day +5 after stem cell retransfusion, 
until the absolute neutrophil count (ANC) was  6 0.5  ! 10 9 cells/l 
for at least 3 consecutive days.
 The BEAM regimen consisted of carmustine 1  ! 300 mg/m 2 , 
etoposide 8  ! 150 mg/m 2 b.i.d., cytarabine 8  ! 200 mg/m 2 b.i.d. 
and melphalan 1  ! 140 mg/m 2 , followed by APBSCT.
 Patients treated for disease entities other than NHL or HL and 
patients receiving a dose-reduced BEAM regimen (i.e. ‘BEAM el-
derly’) were excluded from this analysis.
 The medical records of the patients and our prospective trans-
plantation database were screened for length of hospital stay, ap-
pearance and duration of fever, use of intravenous (i.v.) antibiotics 
and need for red blood cell and platelet transfusions during hos-
pital stay. These factors were compared between the groups.
 Neutropenia was defined as ANC  ! 0.5  ! 10 9 cells/l. Fever was 
defined as body temperature  6 38.4   °   C. Every day of fever was 
considered for analysis when a body temperature over this cut-off 
was documented in the patient charts. Hospitalization time was 
defined as time from the day of stem cell reinfusion (day 0) to the 
day of patient discharge.
 Statistical Analyses 
 Statistical comparisons of patient characteristics were made 
using either a Mann-Whitney U test, or a Fisher’s exact test, as 
appropriate. Continuous clinical outcomes are presented as me-
dian (range), and compared using the Mann-Whitney U test, 
while binary clinical outcomes are presented as percentages, and 
compared using Fisher’s exact test. Cost analysis is based on the 
average cost of antibiotics and blood products, average length of 
stay, and average cost of filgrastim or pegfilgrastim per patient 
(compared with Kruskal-Wallis test).
 All analyses were performed in the R programming language 
 [12] .
 Results 
 Patient Demographics 
 Between January 2006 and December 2009, a total of 
54 patients with NHL (n = 40; 74%) or HL (n = 14; 26%) 
Table 1.  Patient characteristics
Parameter Filgrastim
use
(n = 20)
Pegfilgras-
tim use
(n = 34)
p
value
Age, years 0.8
Median 51 51.7
Range 24–67.6 18.8–66.2
Gender, n (%) 0.39
Male 14 (70) 19 (56)
Female 6 (30) 15 (44)
CD34+ cells reinfused, !106 cells/kg b.w. 0.76
Median 5.2 5.3
Range 2.3–12 2.1–20.1
Entity, n (%) 0.49
Non-Hodgkin’s lymphoma 13 (65) 27 (79)
Hodgkin’s lymphoma 7 (35) 7 (21)
NHL subtype, n (%) 0.79
DLBCL 7 (54) 8 (30)
Follicular lymphoma 1 (7.5) 4 (15)
Mantle cell lymphoma 4 (31) 9 (33)
Peripheral T-NHL 1 (7.5) 3 (11)
Anaplastic large T-NHL 0 2 (7)
Dendritic sarcoma 0 1 (4)
C D34 = Cluster of differentiation 34; DLBCL = diffuse large 
B-cell lymphoma.
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were treated with unmodified high-dose BEAM and re-
ceived subsequent G-CSF support. Thirty-four (68%) pa-
tients received single-dose pegfilgrastim, and 20 (32%) 
patients received filgrastim after APBSCT, respectively. 
Filgrastim was applied after APBSCT for a median of 7.5 
days (range 5–16 days). The main patient characteristics 
were well balanced between the 2 groups ( table 1 ).
 Efficacy 
 The median time to neutrophil engraftment after 
pegfilgrastim was identical to the engraftment achieved 
with filgrastim [median 9 days (range 8–22) for pegfil-
grastim vs. 9 days (range 7–13) for filgrastim; p = 0.55], 
and the median duration of neutropenia grade 4 did not 
differ significantly between the 2 patient populations, 
with a median of 7 days (range 5–22) for pegfilgrastim 
versus 8 days (range 5–14) for filgrastim (p = 0.13). In ad-
dition, no difference regarding the duration of thrombo-
cytopenia grade 4 was seen between the 2 groups (me-
dian 7 days, range 3–20, for pegfilgrastim vs. 9.5 days, 
range 2–19, for filgrastim, p = 0.21). Also no significant 
differences were observed regarding the number of red 
blood cell or platelet transfusions, the duration of fever 
and the duration of i.v. antibiotic treatment between the 
2 groups ( table 2 ).
 In the binary outcome analysis, no significant differ-
ence was noted in the number of patients needing i.v. an-
tibiotics or blood products. In addition, there were no dif-
ferences regarding the incidence of fever or the need for 
transfer to the intensive care unit between the 2 groups 
( table 3 ).
 Cost Analysis 
 Cost analysis was performed using the Swiss drug 
prices listed for the year 2008. The median cost per pa-
tient for filgrastim was 1,950 Swiss francs (CHF), com-
pared with CHF 2,077 for pegfilgrastim (p = 0.16, Mann-
Whitney U test). An integrated cost analysis including 
the costs of G-CSF used, the infused blood products and 
the hospital stay showed an additional expenditure of 
12% for patients receiving pegfilgrastim during the post-
transplant period, without being statistically significant 
(p = 0.38, Mann-Whitney U test).
 Discussion 
 Our study objective was to assess the impact of pegfil-
grastim on the clinical outcome of patients with NHL or 
HL who received unmodified BEAM as conditioning 
regimen followed by subsequent stem cell retransfusion.
Table 3.  Clinical outcomes (binary) in lymphoma patients treated 
with BEAM
Parameter Filgrastim
(n = 20)
Pegfilgrastim
(n = 34)
p
value
Intravenous antibiotics 18 (90) 34 (100) 0.13
Incidence of fever 16 (80) 33 (97) 0.057
Red blood cell transfusions 17 (85) 28 (82.5) 1
Platelet transfusions 20 (100) 34 (100) 1
Transfer to ICU 1 (5) 3 (9) 1
D ata presented as absolute patient numbers with percentages 
in parentheses. p values from Fisher’s exact test. ICU = Intensive 
care unit.
Table 2.  Clinical outcomes in lymphoma patients treated with BEAM
Parameter Filgrastim use
(n = 20)
Pegfilgrastim use
(n = 34)
p value
Length of hospital stay, days 16 (11–35) 16.5 (12–32) 0.27
Time to engraftment, days 9 (7–13) 9 (8–22) 0.55
Duration of neutropenia grade 4, days 8 (5–14) 7 (5–22) 0.13
Duration of thrombocytopenia grade 4, days 9.5 (2–19) 7 (3–20) 0.21
Duration of fever, days 2 (0–19) 4.5 (0–16) 0.057
Duration of i.v. antibiotic treatment, days 10 (0–23) 11 (4–28) 0.75
Red blood cell transfusions, n 4 (0–13) 2 (0–9) 0.27
Platelet transfusions, n 2 (1–8) 2.5 (1–8) 0.78
Data presented as median (range). p values from Mann-Whitney U test.
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 In our analysis of a homogenous patient collective
we showed that administration of pegfilgrastim after 
high dose BEAM and APBSCT is as efficacious as fil-
grastim. We did not find differences regarding time to 
engraftment, length of hospital stay or the need for 
blood products and i.v. antibiotics. This finding is in ac-
cordance with studies demonstrating similar efficacy of 
pegfilgrastim and filgrastim in patients who received 
conventionally dosed myelosuppressive chemotherapy 
 [13–14] .
 To our knowledge, this is the largest analysis so far fo-
cusing exclusively on patients receiving unmodified 
BEAM as conditioning regimen followed by APBSCT, 
and we were able to demonstrate that pegfilgrastim is not 
inferior to filgrastim. The available data so far on this 
topic have been achieved by analyzing heterogenous pa-
tient cohorts treated with different conditioning regi-
mens  [15–17] . Recently, a study focused on lymphoma 
 patients who received BEAM or BEAC (conditioning 
 regimen with carmustine, etoposide, cytarabine and cy-
clophospamide) as conditioning regimen  [18] . However, 
high-dose chemotherapy regimens differ in terms of tox-
icities, and the results of the patient outcome during the 
post-transplant period are likely to be influenced primar-
ily by this heterogeneity  [9–11, 19] .
 The median cost of filgrastim needed to achieve an 
engraftment was lower than the cost of a single-dose of 
pegfilgrastim, and this additional expenditure could not 
be counterbalanced by a shortening of the hospital stay or 
less supportive measures like i.v. antibiotics or blood 
products. In an integrated cost analysis we observed an 
additional expenditure of 12% for patients treated with 
pegfilgrastim, although this difference did not meet sta-
tistical significance.
 To conclude, in our experience, pegfilgrastim appears 
to be equivalent to filgrastim after conditioning chemo-
therapy with high-dose BEAM followed by APBSCT. We 
did not see any differences regarding time to engraft-
ment, the length of hospital stay or the need for i.v. anti-
biotics and blood products. Pegfilgrastim may be consid-
ered as a therapeutic option in patients treated with 
BEAM and APBSCT.
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